Hydroxychloroquine plaquenil pharmacological drug class

Discussion in 'Discount Prescriptions' started by morok, 23-Feb-2020.

  1. KolikNOW XenForo Moderator

    Hydroxychloroquine plaquenil pharmacological drug class


    Falciparum Discontinue in 6 months if improvement is inadequate Use in patients with psoriasis may precipitate a severe attack of psoriasis; use with caution Postmarketing cases of life-threatening and fatal cardiomyopathy reported with use of hydroxychloroquine as well as of chloroquine Irreversible retinal damage observed in some patients who had received hydroxychloroquine sulfate; significant risk factors for retinal damage include daily doses of hydroxychloroquine sulfate greater than 6.5 mg/kg (5 mg/kg base) of actual body weight, durations of use greater than five years, subnormal glomerular filtration, use of some concomitant drug products such as tamoxifen citrate and concurrent macular disease Ocular examination is recommended within first year of therapy; baseline exam should include: best corrected distance visual acuity (BCVA), an automated threshold visual field (VF) of the central 10 degrees (with retesting if an abnormality is noted), and spectral domain ocular coherence tomography (SD-OCT) For individuals with significant risk factors (daily dose of hydroxychloroquine sulfate 5.0 mg/kg base of actual body weight, subnormal glomerular filtration, use of tamoxifen citrate or concurrent macular disease) monitoring should include annual examinations which include BCVA, VF and SD-OCT; for individuals without significant risk factors, annual exams can usually be deferred until five years of treatment In individuals of Asian descent, retinal toxicity may first be noticed outside macula; in patients of Asian descent, it is recommended that visual field testing be performed in central 24 degrees instead of central 10 degrees Hydroxychloroquine should be discontinued if ocular toxicity is suspected and patient should be closely observed given that retinal changes (and visual disturbances) may progress even after cessation of therapy Hepatic disease or alcoholism Glucose-6-phosphate dehydrogenase (G6PD) deficiency is associated with hemolysis and renal impairment; use with caution Dermatologic reactions to hydroxychloroquine may occur Patients are prone to dermatitis outbreaks Signs or symptoms of cardiac compromise have appeared during acute and chronic treatment; clinical monitoring for signs and symptoms of cardiomyopathy is advised, including use of appropriate diagnostic tools such as ECG to monitor patients for cardiomyopathy during therapy; if cardiotoxicity is suspected, prompt discontinuation may prevent life-threatening complications Not for administration with other drugs that have potential to prolong QT interval; hydroxychloroquine prolongs QT interval; ventricular arrhythmias and torsades de pointes reported in patients taking hydroxychloroquine Skeletal muscle myopathy or neuropathy leading to progressive weakness and atrophy of proximal muscle groups, depressed tendon reflexes, and abnormal nerve conduction, reported; muscle and nerve biopsies have been associated with curvilinear bodies and muscle fiber atrophy with vacuolar changes; assess muscle strength and deep tendon reflexes periodically in patients on long-term therapy Suicidal behavior rarely reported in patients treated with hydroxychloroquine Hematologic reactions (including aplastic anemia) and agranulocytosis may occur May exacerbate heart failure Shown to cause severe hypoglycemia including loss of consciousness that could be life threatening in patients treated with or without antidiabetic medications; warn patients about risk of hypoglycemia and associated clinical signs and symptoms; patients presenting with clinical symptoms suggestive of hypoglycemia during treatment should have their blood glucose checked and treatment reviewed as necessary A reduction in dosage may be necessary in patients with hepatic or renal disease, as well as in those taking medicines known to affect these organs Use with caution in patients with hepatic disease or alcoholism or in conjunction with known hepatotoxic drugs Consider discontinuing therapy if any severe blood disorder such as aplastic anemia, agranulocytosis, leukopenia, or thrombocytopenia, which is not attributable to the disease under treatment appears; perform periodic blood cell counts if patients are given prolonged therapy Pregnancy category: C Lactation: Drug is concentrated in breast milk (American Academy of Pediatrics committee states that it is compatible with nursing) A: Generally acceptable. Contact the applicable plan provider for the most current information. Controlled studies in pregnant women show no evidence of fetal risk. Either animal studies show no risk but human studies not available or animal studies showed minor risks and human studies done and showed no risk. Animal studies show risk and human studies not available or neither animal nor human studies done.

    Malaria chemoprophylaxis chloroquine phosphate tablet 500 mg in the news Hydroxychloroquine and metformin

    PrPLAQUENIL® Hydroxychloroquine Sulfate Tablets USP 200 mg ACTIONS AND CLINICAL PHARMACOLOGY PLAQUENIL hydroxychloroquine sulfate tablets belongs to the 4-aminoquinoline class. PLAQUENIL has been beneficial for patients with rheumatoid arthritis and lupus erythematosus, especially chronic discoid lupus. It belongs to a class of medications known as disease-modifying antirheumatic drugs DMARDs. It can reduce skin problems in lupus and prevent swelling/pain in arthritis, though it is not known. PLAQUENIL prescription and dosage sizes information for physicians and healthcare professionals. Pharmacology, adverse reactions, warnings and side effects.

    Unknown; may impair complement-dependent antigen-antibody reactions; inhibits locomotion of neutrophils and chemotaxis of eosinophils Increases p H and interferes with lysosomal degradation of hemoglobin, which in turn interferes with digestive vacuole function Bioavailability: Rapid and complete absorption Onset: May take 4-6 months to show response; peak response takes several months (rheumatic disease) Duration: Unknown Peak plasma time: 1-3 hr Protein bound: 55% Metabolites: Desethylhydroxychloroquine, desethylchloroquine Half-life: 32-50 days Excretion: Urine (60%) The above information is provided for general informational and educational purposes only. D: Use in LIFE-THREATENING emergencies when no safer drug available.

    Hydroxychloroquine plaquenil pharmacological drug class

    Hydroxychloroquine Plaquenil, Plaquenil Oral Uses, Side Effects, Interactions, Pictures, Warnings.

  2. Plaquenil 200 mg wikipedia
  3. Hydroxychloroquine trade name
  4. Inj chloroquine dose
  5. Mechanism of action of hydroxychloroquine as an antirheumatic drug. Fox RI1. Author information 1Department of Rheumatology, Scripps Clinic and Research Foundation, La Jolla, CA 92037. The antimalarial agents chloroquine and hydroxychloroquine have been used widely for the treatment of rheumatoid arthritis and systemic lupus erythematosus.

    • Mechanism of action of hydroxychloroquine as an..
    • PLAQUENIL Dosage & Rx Info Uses, Side Effects.
    • PLAQUENIL hydroxychloroquine sulfate Label.

    Hydroxychloroquine belongs to two drug classes antimalarial and disease-modifying anti-rheumatic drugs DMARDs. As an antimalarial, hydroxychloroquine is used to treat malaria. It may also be used to help prevent malaria in areas where other preventive medicines are known not to work. Urine hydroxychloroquine levels were still detectable after 3 months with approximately 10% of the dose excreted was parent drug. Results following a single dose of a 200 mg tablet versus i.v. infusion 155 mg, demonstrated a halflife of about 40 days and a large volume of distribution. Hydroxychloroquine is in a class of drugs called antimalarials. It is used to prevent and treat acute attacks of malaria. It is also used to treat discoid or systemic lupus erythematosus and rheumatoid arthritis in patients whose symptoms have not improved with other treatments.

     
  6. AcoolA Well-Known Member

    Hello, I was recently told by my internal medicine doctor, after years of cataloging symptoms, that she was going to begin treating me for Lupus. Plaquenil side effects - kidney problems? - Symptoms. PLAQUENIL Patient Assistance Program Stomach problems with Plaquenil • Johns Hopkins Arthritis Center
     
  7. saljeri New Member

    Inflammatory Osteoarthritis And Plaquenil Nov 28, 2010 This "dendritic deactivation" I made that phrase up helps reduce your immune system being silly and inflaming your joints. My sister was dx'd with Inflammatory Arthritis and Plaquenil sent her into remission some years ago now. Though it's my personal opinion that she actually has Psoriatic Arthritis and a Rheumy of limited intellect!

    PLAQUENIL Side Effects, Reviews by Patients -
     
  8. HecySkalaySic Moderator

    Hydroxychloroquine Plaquenil Success, Reviews and Side Effects Hydroxychloroquine side effects may vary greatly from very mild side effects that go away with time to severe side effects like eye damage, ear damage, or heart problems. Some side effects may be experienced as the body adjusts to hydroxychloroquine but may diminish as the body becomes used to the drug.

    Plaquenil Hydroxychloroquine - Side Effects, Dosage.